コメントを投稿するにはログインが必要です
ログインページへ記事ができると、章ごとの要約と、聴きどころへ飛べる目次がここに並びます。いまは音声で聴けます。
#6-18E. Navigating GLP-1 Receptor Agonist Use in Pregnancy and Lactation (ACOG, 2026)
2026年11月6日 13:00·5分3秒
As the prepregnancy and inadvertent early-pregnancy use of GLP-1 receptor agonists rapidly increases, clinicians face critical management decisions regarding maternal and fetal safety. This ACOG Practice Advisory advises discontinuing GLP-1RAs one to two months before conception and avoiding their use during pregnancy due to limited human safety data, while noting that current evidence stems exclusively from observational studies with inherent risk of confounding. These consensus recommendations provide clinicians with a clear framework to navigate preconception counseling, address inadvertent early exposure, and optimize perinatal outcomes.
Citation: American College of Obstetricians and Gynecologists (ACOG), LaCoursiere DY. Use of Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy and Lactation. ACOG Practice Advisory. 2026.
DOI: N/A (ACOG Practice Advisory)
Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.
